Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fenretinide (ISLA101) in dengue virus challenge
NCT06528457Phase 2Completed
- Sponsor
- Island Pharmaceuticals
- Start
- Sep 2024
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of fenretinide in dengue fever (4 cohorts), sponsored by Island Pharmaceuticals. Primary endpoint: Dengue virus viremia following inoculation at 29 days. Started Sep 2024; status: completed.
02
Drugs
fenretinide
03
Conditions
dengue fever
Beyond the preview
Go deeper on NCT06528457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06528457.